Pay in 4 interest-free payments of $5.07 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
Our facility accepts all major insurance plans, handles prior authorizations entirely, and offers telehealth services for your convenience
The app's focus on protein-first eating aligns with clinical recommendations for patients experiencing medication-induced appetite suppression
Our team checks your eligibility and pairs you with a suitable provider
tendon rupture or injury
| Category | Zepbound | Mounjaro | |-----------------------------------|------------------------------------------------|------------------------------------------------| | FDA Approval Indication | Obesity and overweight management (with comorbidities) | Type 2 diabetes management | | Year of FDA Approval | 2023 | 2022 | | Active Ingredient | Tirzepatide | Tirzepatide | | Dose Range | 2.5 mg to 15 mg once weekly | 2.5 mg to 15 mg once weekly | | Primary Clinical Purpose | Weight loss | Blood sugar control | | GLP-1/GIP Activity | Dual agonist (GLP-1 + GIP) | Dual agonist (GLP-1 + GIP) | | Average Weight Loss (in trials) | Up to 22.5% of body weight in SURMOUNT-1 study | Up to 15% of body weight in SURPASS studies | | Insulin Sensitivity Impact | Improves insulin sensitivity in patients with obesity | Improves insulin sensitivity in type 2 diabetes patients | | Delivery Method | Single-use auto-injector pen, subcutaneous injection | Single-use auto-injector pen, subcutaneous injection | | Dosing Frequency | Once weekly | Once weekly | | Manufacturer | Eli Lilly | Eli Lilly | | Common Side Effects | Nausea, vomiting, diarrhea, constipation, decreased appetite | Nausea, vomiting, diarrhea, constipation, decreased appetite | | Insurance Coverage | Variable
